INTRODUCTION
Haemophilia has been known since biblical times as an inherited bleeding condition, as boys born into families known to have the disease were excluded from ritual circumcision in the third century a d (quoted by McKee, 1983) . The pattern of inheritance whereby males were affected, whereas females were not (although they could transmit the disease to future generations), intrigued the 19th century biologists and was not adequately explained until the genetic basis of sex was understood. The clinical symptoms of the disease can be very serious and were lifethreatening before replacement therapy was available. Internal bleeding occurred into muscles and joints, often without obviously following any trauma and patients could die of massive internal haemorrhage. Haemophilia A and B pose identical clinical pictures and both show a similar X-linked pattern of inheritance. Their differential diagnosis depends on laboratory clotting tests and they were first clearly distinguished in 1952. Subsequent work showed that the former condition involved defects in the protein factor VIIIC and the latter in factor IX. Both proteins function in the middle phase of the intrinsic clotting cascade (Fig. 1) . Haemophilia A is the commoner disease, occurring in Caucasians in approximately one in 5000 males, and is also referred to as classical haemophilia. Haemophilia B occurs in approximately 1 in 30000 males and is also known as Christmas disease, after the name of a patient, Stephen Christmas, in whom the disease was characterized early on.
Between 1960 and 1980 the methods of analysing the sequence of amino acids in proteins that had been pioneered by Sanger and his colleagues on insulin were applied to the proteins of the clotting cascade, including the factor IX protein. By 1979 the entire amino acid sequence of the bovine factor IX was known (Katayama et al. 1979 ) and there was evidence suggesting that a rather similar sequence might be present in humans. This was a considerable feat of work because of the low yield (about 5 jUgml-1 of the protein) in plasma. But this basic knowledge of protein structure was not as easily obtained for factor VIIIC, partly because of its minute yield in plasma, but also because its high molecular weight and instability made it particularly difficult to characterize. In fact, factor VIIIC exists as a minor component of the high molecular weight complex referred to as factor VIII, and the bulk of this complex is composed of another protein, the von Willebrand factor.
In this short review, I will briefly describe and discuss the advances made since 1980 that have enabled the genes for factor VIIIC and IX to be isolated by recombinant DNA methods. I will then describe progress in the uses of such gene probes in clinical diagnosis of carriers, as well as their use for studying the molecular pathology of the disease and the production of genetically engineered protein.
CLONING AND CHARACTERIZATION OF THE GENES FOR FACTORS VIIIC AND IX
In the period between 1970 and 1980, considerable advances were made in the purification of messenger RNA from highly specialized cells, such as the a and ¡3 globin mRNA from reticulocytes. It became possible to clone these highly enriched mRNA preparations, first by making complementary DNA, or cDNA, copies of the mRNA, and then subsequently converting this material to double-stranded DNA in vitro and cloning in plasmid or in phage A vectors propagated in the bacterium, Escherichia coli. Subsequently, these cDNA clones could be characterized and used to isolate and study the gene organization. For clotting factor IX, a different approach was necessary as its messenger RNA was present in extremely low concentrations in liver. Nevertheless, using the approach of synthesizing short oligonucleotide probes based on a knowledge of the amino acid sequence of portions of the protein, the problem became soluble. We synthesized oligonucleotide probe mixtures for several regions of the bovine factor IX sequence to enable the isolation The extrinsic pathway (activation of X by activated VII) is also shown. This is a simplified version showing the main features, but it omits feedback loops and a step, e.g. factor V ila activation of IX, interconnecting the two pathways (from Austen & Rhymes, 1975, with permission For factor VIIIC a variation on the method of using oligonucleotide probes was used. Because there was some uncertainty as to which tissue to use as a source of mRNA in the preparation of factor VUIC-containing cDNA libraries of clones, both groups who successfully cloned and characterized the factor VIIIC gene chose to isolate the initial clone from a short section of the factor VIIIC gene. It turned out to be extremely long and complicated and is about 186X 103 bases in length, and boasts 26 introns. The mRNA codes for a mature glycoprotein of 2332 amino acids in length. This gene is the largest known to date and occupies approaching 0-1 % of the total length of the X chromosome (Gitschier et al. 1984; Toole et al. 1984). One current limitation of the linkage analysis with RFLPs is that the frequencies of these polymorphisms in the general population, which appear to mimic that in the affected pedigrees, is such that carrier diagnosis is possible as yet on an average of only 68 % of known Caucasian haemophilia B pedigrees and about 50 % of Caucasian haemophilia A pedigrees. Moreover, as the assays are indirect, they rely on the availability of blood samples not only from the potential carrier under investigation but also from a known patient within the pedigree, preferably a brother, as well as from the mother and father. knowing the maximum distance between the polymorphism and gene defect cannot be more than 30X103 bases, there will be an even chance of the linkage being broken in the ratio of 30x3:200xl03 or -1 in 2xl03 times. In percentage terms this is 0-05% chance. For such reasons, we concluded that the indirect linkage analysis w ith intragenic R F LP s is 99-9% accurate for factor IX (W inship et al. 1984) . For factor V IIIC with a gene of approxim ately five times the length of the factor IX gene, the corresponding value is 99-7% . In the clinical situation, where fam ilies and carriers may be counselled, one must remember that this is an average probability and only an approximate calculation, and that there must be a chance, as more families are counselled as a result of these new methods of analysis, that cases will arise in which the linkage is broken and therefore a wrong diagnosis is made.
DIAGNOSIS OF CARRIERS AND PRENATAL DIAGNOSIS OF AFFECTED

INDIVIDUALS
More distantly related RFLP markers, e.g. anonymous DNA probes, have been advocated by some experimentalists for carrier and prenatal diagnosis, particularly in the case of factor VIII (Gitschier et al. 1985a) in which few intragenic RFLPs are known to date. However, a problem with these markers, e.g. D X13 and S tl4 , at a close, but still uncertain (Janco et al. 1986), distance from the disease locus, is that the recombination fraction is not known with sufficient accuracy to make them as reliable diagnostically as specific gene probes. Only if and when 200 to 300 total meioses are studied and the recombination fraction is shown to be less than 1 % would I advocate their use clinically.
If obligatory carriers fail to show heterozygosity for any of the known gene-specific polymorphisms, of course, no accurate information is forthcoming for potential carriers -a situation hardly reassuring for the family under investigation, as they would have to fall back on classical diagnostic methods or somewhat less-reliable diagnostic markers such as D X13 or S tl4 in the case of haemophilia A. One may calculate that if 95 % of all families with haemophilia A or B are to be counselled, a knowledge of at least five different gene-specific RFLPs will be required even if we assume that (1) each RFLP is distributed in the haemophiliac population at the theoretical maximum frequency of 50% , and (2) each RFLP segregates indepen dently. In practice, not all RFLPs are favourably distributed and because of the tendency of adjacent regions of DNA to be inherited in a linked way some of the RFLPs will not be distributed independently of each other in the population at large. This linkage disequilibrium can severely reduce the value of additional RFLPs (as shown for the XmnI polymorphism in factor IX; Winship et al. 1984) when information from a Taql RFLP is already known. Because of such difficulties, which have also been described for the /3-globin locus (Weatherall, 1982), a realistic estimate of the number of RFLPs required in order to 'catch' 95 % of the affected pedigrees is nearer seven to ten. This value will be difficult to achieve in the short term, but in the medium term, say the next 3 -5 years, it should be possible. Of course, a highly polymorphic 'minisatellite' type of sequence such as that occurring near the ar-globin locus (Weatherall, Higgs, Wood & Clegg, 1984) would be ex tremely valuable, but to date there is no evidence of this near the factor VIIIC or IX loci. The current position on factor IX is that a fourth RFLP involving an M nll RFLP is under investigation in Oxford (P. R. Winship, personal communication). Similarly, I am sure that further RFLPs will be found in the much longer factor VIIIC gene. So far, only a few prenatal diagnoses have been performed on foetal chorionic villi or amniotic samples using RFLPs in haemophilia A and B, but as the modern techniques for carrier diagnosis become more available and potential carriers in affected families find out their status, I predict an increasing demand for such antenatal information. The numbers in parentheses refer to the amino acid residues of the protein.
is changed to G-G (P. R. Winship, unpublished). These mutations are very reminiscent of the kind of defect that occurs in the /3-globin gene in /3° thalassaemias (Weatherall et al. 1984)
and it is instructive to note how critical a single point mutation in a vital processing pathway can be, causing as it does clinically severe haemophilia in both affected patients. The third group of patients, which have been studied in detail in haemophilia B and less extensively in haemophilia A, are those that produce inhibitors. We argued that the reason these patients made antibodies was that their immune system had not been made tolerant to normal factor IX and therefore such patients were likely to have gene deletions. . 1983) . However, the position of these critical epitopes in the protein, and the probable differences in detail in the development of tolerance to factor VIIIC and IX remain unknown. Two other clinically severe haemophilia A patients H22 and H51 (see Table 1 ) have been characterized at the molecular level. One is caused by another point mutation, generating an aberrant translation stop codon, and a second is caused by a short deletion at the 3' terminus of the gene (Gitschier et al. 19856) . Neither is an inhibitor patient, but Giannelli & Brownlee (1986) note that the probable effect of these latter two mutations on the protein would be expected to be less than the mutations discussed above in the two patients with inhibitors. To date no patients have been described with defects in the promoter or in the A-A-U-A-A-A polyadenylation region of the gene. Further studies of antigen positive patients should give valuable information about the critical regions for function in both the factor V IIIC and the factor IX molecules. Factor IX and its activated form IXa have to interact with at least five other molecules in the m iddle stage in the intrinsic clotting pathway, so we m ust expect m any parts of the molecule to be critical for function and, or, correct folding of the protein. Sim ilar argum ents apply to factor V IIIC , although in this case we sus pect that the central carbohydrate-rich portion of this very large molecule is less im portant functionally than the rest of the molecule, as it has diverged extensively in amino acid sequence among mammals (Orr et al. 1985) .
REGIONAL LOCALIZATION ON THE X CHROMOSOME Fig. 4 shows the localization of the factor IX locus (labelled FIX ) to band q27 near to the tip of the long arm of the X chromosome. The localization was discovered using cloned factor IX probes (e.g. see Boyd et al. 1984) and has been more recently refined to band q27.1 by in situ hybridization to extended early metaphase chromosomes (V. J. Buckle, personal communication). T he short cytogenetic distance from the locus at q27.3 for mental retardation with macro-orchidism associated with fragility (F S) is clear. U nfortunately, however, there is still too much recombination (20 %) between the factor IX locus and the FS for the factor IX probes to have any real value in carrier diagnosis of this rather common and depressing disease (e.g. see Choo et al. 1984 ). The haemophilia A locus (HEMA) is known to be closely linked to a group of three other markers; glucose-6-phosphate dehydrogenase (G6PD), colour blindness (CB) and adrenoleukodystrophy (ALD), but again the recombinational fraction between haemophilia A and FS is too great for the factor VIII probes to be useful in diagnosis of the mental retardation syndrome. Many other anonymous gene markers are now known for this region of the X chromosome, but those that have been tested so far are no closer to the FS locus than factor IX. A closely linked probe or a specific gene probe is urgently needed.
GENETICALLY ENGINEERED FACTORS VIIIC AND IX
Haemophilia A and B patients need regular injections of factors VIIIC and IX if haemorrhage is to be avoided and controlled. Unfortunately, there is risk of viral contamination introduced in the donor blood used for these preparations, which has not been completely removed in the purification procedure. Recently, AID S has superseded hepatitis B and the non-A, non-B hepatitis as the most hazardous complication of therapy. Although the AID S virus is fortunately rather heat-labile, we do not yet know how successful the heat treatment (instituted in 1985) will be and whether other viruses might appear from time to time that cannot be so easily inactivated. It is therefore highly desirable to produce the required proteins from a genetically engineered source non-contaminated with viruses. This should in addition give a well-standardized product and manufacturers would no longer need to rely on blood donors for their starting material.
The ability to produce factor VIII in vitro from cloned DNA was first . Both liver and kidney cells successfully produced active material, although the specific activity of the factor IX protein was higher in the liver cell, presumably reflecting the fact that this cell tissue had correctly modified and processed the factor IX. As liver is the tissue in which factor IX is normally synthesized, it might be expected to be appropriate for correct expression and pro duction of factor IX that is indistinguishable from the raw material. Nevertheless, in all these studies, of both factor VIIIC and IX, minute yields of product are reported. One of the best yields of approaching 1 /¿g of factor IX per ml of medium was reported in one of the papers on factor IX (Busby et al. 1985) . Even with this, I estimate it would be necessary to culture hundreds of thousands of litres of cells to obtain enough material for the U K requirement of 50 g of factor IX for one year. Given that purification of proteins on a large scale necessarily entails losses, it is clear that more efficient small-scale synthesis has to be developed before an investment in a large-scale industrial process is made. Fortunately, there is an indication that a protein related to factor IX (the anti-coagulant protein C) can be successfully produced in high yields in Chinese hamster ovary cells using recombinant DNA methods. In these cells the protein C gene copy number can be amplified by linkage of the clone to the gene for dihydrofolate reductase followed by growth of cells in methotrexate. Thus it may be possible to produce cell lines giving at least 10 times more factor IX. For factor VIIIC, there is a similar requirement for maximization of the yields of genetically engineered material on a small scale.
I estimate that it will be 3 -5 years before the necessary industrial processes for factors VIIIC and IX will be developed and the material adequately characterized and tested for clinical application to human beings. Nevertheless, the product should be safer, free of viruses, and, I suggest, will supersede traditional products made from blood with all their inherent problems. G. G. (1985) . Haemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene. N ature, Lond. 316, 643-645. T o o l e , J. J., K n o p f , J. L ., W o s n e y , J. M ., S u l t z m a n , L. A . , B u e c k e r , J. L., P it t m a n , D . D ., K a u f m a n , R. J., B r o w n , E., S h o e m a k e r , C ., O r r , E. C ., A m p h le t t , G. (1985) . Nucleotide sequence of the gene for human factor IX (antihaemophilic factor B). B iochem istry 24, 3736.
